Connect with us

Hi, what are you looking for?


Novo Nordisk to Acquire Dicerna Pharmaceuticals in $3.3B Deal

Stock Markets17 minutes ago (Nov 18, 2021 10:10AM ET)

(C) Reuters.

By Sam Boughedda — Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares have opened 78% above Wednesday’s close after the company said it has agreed to be acquired by Danish drug maker Novo Nordisk A/S (NYSE:NVO) for $3.3 billion.

“Since the start of our collaboration two years ago, the Dicerna and Novo Nordisk teams have established a strong rapport built on a foundation of mutual respect for one another’s capabilities, culture and expertise,” said Douglas Fambrough, Founder, President, and CEO of Dicerna.

Dicerna shares are trading at $37.94 in the morning session.

Novo Nordisk will acquire all of the outstanding shares of Dicerna common stock for $38.25 per share in cash.

Novo’s strategic move will expand its use of Dicerna’s ribonucleic acid interference (RNAi) platform. Dicerna develops RNAi-based therapies to selectively silence genes that can cause or contribute to disease.

Novo also knows Dicerna well, having entered a research collaboration with the company to discover and develop RNAi therapies using its GalXC RNAi platform technology.

Dicerna told investors that Novo Nordisk expects to initiate clinical development of the first investigational RNAi therapeutic from this collaboration in 2022.

“The combination of Dicerna’s expertise in RNAi and oligonucleotide therapeutics and highly skilled employees with Novo Nordisk’s industry leadership in developing and commercializing medicines to treat serious chronic diseases, has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all our stakeholders,” added Farmbrough.

The companies expect to close the transaction in the fourth quarter of 2021.

Novo Nordisk to Acquire Dicerna Pharmaceuticals in $3.3B Deal

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

World News

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered...

World News

George Soros and Bill Gates are part of a consortium acquiring a British developer of rapid-testing technology, including for Covid-19 and tropical diseases,...


If you parked your car in one of the thousands of parking spots across Calgary, there’s a good chance you paid the Calgary Parking...


ForexMay 27, 2021 02:04AM ET (C) Reuters. By Peter Nurse — The dollar edged higher in early European trade Thursday, finding support from...

Disclaimer: it's managers and its employees (collectively "The Company") do not make any guarantee or warranty about what is advertised or above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. Copyright © 2021 Your Morning Voice. All Rights Reserved